Berkeley -- A research team led by engineers at the University of California, Berkeley, has developed a new mobile phone microscope that uses video to automatically detect and quantify infection by parasitic worms in a drop of blood. This next generation of UC Berkeley's CellScope technology could help revive efforts to eradicate debilitating diseases in Africa by providing critical information for health providers in the field.
"We previously showed that mobile phones can be used for microscopy, but this is the first device that combines the imaging technology with hardware and software automation to create a complete diagnostic solution," said Daniel Fletcher, associate chair and professor of bioengineering, whose UC Berkeley lab pioneered the CellScope. "The video CellScope provides accurate, fast results that enable health workers to make potentially life-saving treatment decisions in the field."
The UC Berkeley engineers teamed up with Dr. Thomas Nutman from the National Institute of Allergy and Infectious Diseases, and collaborators from Cameroon and France to develop the device. They conducted a pilot study in Cameroon, where health officials have been battling the filarial, or parasitic worm, diseases onchocerciasis (river blindness) and lymphatic filariasis.
The video CellScope, which uses motion instead of molecular markers or fluorescent stains to detect the movement of worms, was as accurate as conventional screening methods, the researchers found. The results of the pilot study, performed in Cameroon, are reported in a paper to be published Wednesday, May 6, in the journal Science Translational Medicine.
"This research is addressing neglected tropical diseases," said Fletcher. "It demonstrates what technology can do to help fill a void for populations that are suffering from terrible, but treatable diseases."
Battling parasitic worms
River blindness is transmitted through the bite of blackflies and is the second leading cause of infectious blindness worldwide. Lymphatic filariasis, spread by mosquitoes, leads to elephantiasis, a condition marked by painful, disfiguring swelling in parts of the body. It is the second leading cause of disability worldwide and, like river blindness, is highly endemic in certain regions in Africa.
The antiparasitic drug ivermectin, or IVM, can be used to treat these diseases, but mass public health campaigns to administer the medication have been stalled because of potentially fatal side effects for patients co-infected with Loa loa, which causes loiasis, or African eye worm. When there are high circulating levels of microscopic Loa loa worms in a patient, treatment with IVM can lead to brain or other neurologic damage that can be severe or fatal.
The standard method of screening for levels of Loa loa involves trained technicians manually counting the worms in a blood smear using conventional laboratory microscopes, making the process impractical for use in field settings and in mass campaigns to administer IVM.
The serious side effects of Loa loa and the difficulty of rapidly quantifying Loa levels in patients before treatment make it too risky to broadly administer IVM, representing a major setback in the efforts to eradicate river blindness and elephantiasis.
Next generation CellScope uses video, automation
For this latest generation of the mobile phone microscope, named CellScope Loa, the researchers paired a smartphone with a 3D-printed plastic base where the sample of blood is positioned. The base includes LED lights, microcontrollers, gears, circuitry and a USB port.
Control of the device is automated through an app the researchers developed for this purpose. With a single touch of the screen by the healthcare worker, the phone communicates wirelessly via Bluetooth to controllers in the base to process and analyze the sample of blood. Gears move the sample in front of the camera, and an algorithm automatically analyzes the telltale "wriggling" motion of the worms in video captured by the phone. The worm count is then displayed on the screen.
Fletcher said previous field tests revealed that automation helped reduce the rate of human error. The procedure takes about two minutes or less, starting from the time the sample is inserted to the display of the results. Pricking a finger and loading the blood onto the capillary adds an additional minute to the time.
The short processing time allows health workers to quickly determine on site whether it is safe to administer IVM.
"The availability of a point-of-care test prior to drug treatment is a major advance in the control of these debilitating diseases," said aquatic ecologist Vincent Resh, a professor at UC Berkeley's Department of Environmental Science, Policy and Management. "The research offering a phone based app is ingenious, practical and highly needed."
Resh, who is not involved in the CellScope project, has worked in West Africa for 15 years on the control of onchocerciasis.
The researchers are now expanding the study of CellScope Loa to about 40,000 people in Cameroon.
Co-lead authors of the study are Michael D'Ambrosio, UC Berkeley research scientist in bioengineering, and Matthew Bakalar, UC Berkeley graduate student in bioengineering. Other study authors included researchers from the University of Yaoundé in Cameroon and the University of Montpellier in France.
The Bill and Melinda Gates Foundation, UC Berkeley Blum Center for Developing Economies, U.S. Agency for International Development and NIAID helped support this work. The NIAID is part of the National Institutes of Health.